BerGenBio to hold business update conference call
- Management to provide clinical and financial updates, and outline proposed rights issue - - Webcast will take place on Monday, May 15, 2023, at 10 a.m. CEST - BERGEN, Norway, May 9, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that it will hold a business update conference call on Monday, May 15, 2023, at 10 a.m. CEST. BerGenBio’s senior management team will provide a briefing via a webcast presentation on the Company’s website, followed by a Q&A